Patients with poorly controlled type 2 diabetes despite being on dulaglutide had better outcomes if they switched to tirzepatide than if they upped their dulaglutide dose. In this randomized trial, ...

Results from the phase 3 AWARD-11 trial evaluating higher doses of dulaglutide showed superior HbA1c and body weight reductions with an investigational 4.5mg dose in patients with type 2 diabetes (T2D ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The FDA approved two additional doses of the once-weekly ...

Switching to tirzepatide linked to additional reduction in HbA1c, weight loss compared with escalating dulaglutide. HealthDay News — For patients with inadequately controlled type 2 diabetes receiving ...

Adults with poorly controlled type 2 diabetes assigned higher, investigational doses of the GLP-1 receptor agonist dulaglutide experienced greater improvements in glycemic response and body weight ...

About 3 times as many of the children and teenagers taking dulaglutide had a glycated hemoglobin level of less than 7.0% at 26 weeks compared with those on placebo. Treatment with a once-weekly dose ...

Patients on tirzepatide also experienced more metabolic benefits, such as greater reductions in weight and HbA1c, compared ...

AWARD-11 showed 3.0 mg and 4.5 mg doses led to additional blood sugar control; as a secondary endpoint, both doses also led to weight loss INDIANAPOLIS, Sept. 3, 2020 /PRNewswire/ -- The U.S. Food and ...

The drug was as good as a proven GLP-1, giving doctors another potent option for patients with type 2 diabetes and ...